The CAR T cell 19 trial done by the National Cancer Institute yielded amazing results. Out of 46 patients with refractory relapse leukemia given a single dose of CDR 19 CAR T cells, 65% had a complete response rate. The NCI study even showed the eradication of leukemia that had gone to the spinal fluid and even the brain.

Dr Lee meets with eCancerTV at Childhood Cancer 2016 to discuss results from clinical trials of immunotherapies for neuroblastoma and acute lymphoblastic leukaemia. He describes CD19 T cells successfully treating leukaemia within the cerebrospinal fluid, and the ongoing recruitment of patients for GD2 CAR T cell treatment for osteosarcoma and neuroblastoma.

NCI CARs for childhood ALL and neuroblastoma: the promise and potential pitfalls

Trading The News: CAR T Cells In The News